40 unknown. 40 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 40 | Unknown 40 |
| Phase 1 | 6 | Unknown 6 |
| Phase 3 | 2 | Unknown 2 |
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer Surufatinib,Serplulimab,Etoposide,Carboplatin - Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Fujian Cancer Hospital | 39 | 2023-06-01 | 2023-05-31 |
| SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) SC0245, Irinotecan - Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 67 | 2023-02-23 | 2023-07-14 |
| Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer Surufatinib, Irinotecan - Small Cell Lung Cancer, Angiogenesis | Phase 2 | Unknown | Fujian Cancer Hospital | 40 | 2022-12-01 | 2022-11-29 |
| Immunological Variables Associated to ICI Toxicity in Cancer Patients Checkpoint Blockade, Immune - Breast Cancer, Melanoma | Phase 2 | Unknown | Jules Bordet Institute | 441 | 2022-09-01 | 2023-03-08 |
| Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. Chiauranib - Small Cell Lung Cancer, Advanced Solid Malignant Tumor | Phase 1 / Phase 2 | Unknown | Chipscreen Biosciences, Ltd. | 36 | 2022-08-26 | 2024-07-16 |
| Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer IBI-322 Plus Lenvatinib - Small Cell Lung Cancer | Phase 2 | Unknown | Hunan Province Tumor Hospital | 83 | 2021-12-03 | 2024-01-10 |
| Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy Irinotecan, Simvastatin - Small Cell Lung Cancer | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 40 | 2021-11-01 | 2021-08-09 |
| An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib - Lung Cancer, Small Cell Lung Cancer | Phase 2 | Unknown | Li Zhang, MD | 60 | 2021-08-21 | 2022-02-18 |
| Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy Albumin Paclitaxel, Simvastatin - Small Cell Lung Cancer | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 40 | 2021-07-25 | 2021-07-29 |
| A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer AL8326 tablets - Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Advenchen Laboratories Nanjing Ltd. | 237 | 2020-10-19 | 2021-05-18 |
| A Study of Gimatecan (ST1481) in Small Cell Lung Cancer Gimatecan - Small Cell Lung Cancer | Phase 2 | Unknown | Lee's Pharmaceutical Limited | 70 | 2020-10-01 | 2020-08-06 |
| Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study Anlotinib In Combination With Durvalumab - Anlotinib, Durvalumab | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2020-04-01 | 2020-03-19 |
| Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer Apatinib S-1 - Small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 20 | 2019-10-01 | 2019-10-16 |
| CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) CM082 plus JS001 - Small Cell Lung Cancer | Phase 2 | Unknown | AnewPharma | 30 | 2019-09-18 | 2020-07-09 |
| Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer sintilimab maintenance - Small Cell Lung Cancer, Extensive Disease | Phase 2 | Unknown | Henan Cancer Hospital | 40 | 2019-06-20 | 2020-06-11 |
| Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer Anlotinib Hydrochloride - Small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Changzhou Cancer Hospital of Soochow University | 40 | 2019-05-08 | 2020-01-06 |
| Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC Anlotinib Hydrochloride - Carcinoma, Lung Neoplasm | Phase 2 | Unknown | First Hospital of Shijiazhuang City | 30 | 2019-01-01 | 2018-12-21 |
| Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer Durvalumab - Small Cell Lung Cancer | Phase 2 | Unknown | Samsung Medical Center | 51 | 2018-06-19 | 2020-03-02 |
| NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer. NK cells - Small Cell Lung Cancer | Phase 2 | Unknown | jiuwei cui | 120 | 2018-04-01 | 2018-07-17 |
| Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer Apatinib and Etoposide Capsule - Small Cell Lung Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 60 | 2017-11-29 | 2020-07-10 |
Showing 20 of 40. Sign in to see all of them.
Small Cell Lung Carcinoma (40) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma (2) · Lung Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Renal Cell (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Stomach Neoplasms (1)
Bronchial Neoplasms (40) · Carcinoma, Bronchogenic (40) · Lung Diseases (40) · Neoplasms (40) · Neoplasms by Site (40) · Respiratory Tract Diseases (40) · Respiratory Tract Neoplasms (40) · Thoracic Neoplasms (40) · Lung Neoplasms (38) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
Cisplatin (5) · Etoposide (5) · Irinotecan (5) · apatinib (4) · durvalumab (4) · Albumin-Bound Paclitaxel (2) · Gemcitabine (2) · Simvastatin (2) · Temozolomide (2) · Topotecan (2) · anlotinib (2) · olaparib (2) · surufatinib (2) · 130-nm albumin-bound paclitaxel (1) · Breathing Exercises (1)
Fujian Cancer Hospital (2) · Henan Cancer Hospital (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Advenchen Laboratories Nanjing Ltd. (1) · AnewPharma (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Changzhou Cancer Hospital of Soochow University (1) · Charite University, Berlin, Germany (1) · Chinese Academy of Medical Sciences (1) · Chipscreen Biosciences, Ltd. (1) · First Hospital of Shijiazhuang City (1) · First Hospitals affiliated to the China PLA General Hospital (1) · Fudan University (1) · Gachon University Gil Medical Center (1)
China (26) · United States (4) · South Korea (2) · Belgium (1) · Germany (1) · India (1) · Italy (1) · Japan (1)
Anna Farago, MD, PhD (1) · Anusheel Munshi, MD (1) · Cabilia Pichardo, MD (1) · Chunxia Su (1) · Guanghui Gao (1) · Guosheng Feng, MD (1) · Hailing Yang, MD (1) · Heming Lu, MD (1) · Hui Lin, MD, Phd (1) · Hui Liu, Professor (1) · Jing Ding, Master (1) · Joan M Bull, M.D. (1) · Ming Chen, PHD (1)
PMID 32346071, PMID 12467231, PMID 16170339, PMID 19819917, PMID 21565397, PMID 22722788, PMID 30641276, PMID 32250517, PMID 32742443, PMID 33285097, PMID 33992717, PMID 35500460, PMID 36158690, PMID 41937137, PMID 42601174